GlobeNewsWire
14 Jul 2026, 11:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is facing a class action lawsuit alleging channel stuffing, an undisclosed related party transaction, and inadequate internal controls. — Allegations of accounting fraud and revenue inflation typically lead to severe loss of investor trust and potential regulatory penalties.
-0.80Culper Research report alleged that ADMA's reported 20% growth was a fiction and that real growth was actually -3% in 2025. — A significant discrepancy between reported and actual growth suggests a fundamental overvaluation of the company's business health.
-0.70Cantor Fitzgerald downgraded ADMA Biologics from Overweight to Neutral due to concerns over the short-seller report and the company's response. — A downgrade from a major institutional analyst often triggers further sell-offs and signals a shift in institutional sentiment.
-0.50Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is facing a class action lawsuit alleging securities fraud, channel stuffing, and misleading statements.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2h ago
